19-38647810-C-T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 3P and 11B. PM1PP2BP4_ModerateBP6BS1BS2
The NM_004924.6(ACTN4):c.65C>T(p.Ala22Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000029 in 1,553,566 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_004924.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ACTN4 | NM_004924.6 | c.65C>T | p.Ala22Val | missense_variant | 1/21 | ENST00000252699.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ACTN4 | ENST00000252699.7 | c.65C>T | p.Ala22Val | missense_variant | 1/21 | 1 | NM_004924.6 | A1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152148Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000933 AC: 15AN: 160734Hom.: 0 AF XY: 0.000102 AC XY: 9AN XY: 87810
GnomAD4 exome AF: 0.0000314 AC: 44AN: 1401302Hom.: 0 Cov.: 31 AF XY: 0.0000303 AC XY: 21AN XY: 693224
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152264Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74450
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 17, 2022 | The c.65C>T (p.A22V) alteration is located in exon 1 (coding exon 1) of the ACTN4 gene. This alteration results from a C to T substitution at nucleotide position 65, causing the alanine (A) at amino acid position 22 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Nephrotic syndrome Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Sydney Genome Diagnostics, Children's Hospital Westmead | Apr 18, 2014 | This patient is heterozygous for a variant of unknown clinical significance (VOUS), c.65C>T (p.Ala22Val), in the ACTN4 gene. To our knowledge, this variant has no frequency data and has not been previously reported in the literature to be associated with disease. p.Ala22, is a weakly conserved amino acid (up to 11 species) and there is only a small physicochemical difference between the wild type alanine and mutant valine. In silico analysis (Alamut Visual v2.6) varies regarding this variant; while PolyPhen2 predicts this variant to be possible damaging, SIFT, Align GVGD and Mutation Taster all suggest that this variant is likely to be benign. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 25, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at